Why PTC Therapeutics Shares Skyrocketed 20.6% Today

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 19 September, 2016 by The TZ Newswire Staff

Why PTC Therapeutics Shares Skyrocketed 20.6% Today

Image source: PTC Therapeutics.

After competitor Sarepta Therapeutics (NASDAQ: SRPT) won early approval of Exondys 51, a drug for Duchenne muscular dystrophy (DMD), investors sent PTC Therapeutics (NASDAQ: PTCT) shares soaring 20.6% today.

See also
- Next Article Obama Explains Why The Presidential Race Is Such A "Nail-Biter"
- Previous Article Better read this headline carefully: FedEx details plans to raise rates next year
Editorial Calender

September 2016

M T W T F S S

1 2 3 4

5 6 7 8 9 10 11

12 13 14 15 16 17 18

19 20 21 22 23 24 25

26 27 28 29 30

« Aug Oct »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar

The Traderszone Network

Editorial Archives

Published in TZ Latest News 19 September, 2016 by The TZ Newswire Staff

Why PTC Therapeutics Shares Skyrocketed 20.6% Today

See also

Editorial Calender

Recent Tags